<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01268943</url>
  </required_header>
  <id_info>
    <org_study_id>CH-GI-013</org_study_id>
    <nct_id>NCT01268943</nct_id>
  </id_info>
  <brief_title>Study of Postoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients</brief_title>
  <official_title>Phase 1 Study of Postoperative Capecitabine With Concurrent Radiation in Elderly With Stage II/III Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to seek the proper dose of capecitabine in post-operative
      concurrent chemotherapy for stage II/III elderly rectal cancer patients receiving radical
      surgery, and evaluate the toleration of this modality in such patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For those &quot;younger&quot; locally advanced (stage II/III) rectal cancer patients (usually means
      patients less than 70), it is suggested that after radical surgery, patients should receive
      concurrent chemo-radiation. Capecitabine is a widely used chemotherapy medicine under such
      condition. Based on experience, the investigators think this modality can also be tolerated
      by patients over 70, and will increase local control rate as which has been proved in younger
      ones. As the first step to test this hypothesis, we designed this phase I study to seek the
      proper dose of capecitabine, a widely used oral chemotherapy medicine, in postoperative
      concurrent chemo-radiation for stage II/III rectal cancer patients over 70, and to evaluate
      the safety of this modality in this group of patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Related Toxicity</measure>
    <time_frame>up to 9 weeks</time_frame>
    <description>dose related toxicity is defined as follows:1. WBC damage &gt;= grade 3; granular cell decrease &gt;= grade 3; hemoglobin &gt;= grade 2; platelet &gt;= grade 2;SGPT/SGOT elevation &gt;= grade 2; ALP &gt;= grade 2; GGT &gt;= grade 2; Tbil &gt;= grade 2;renal function damage: BUN/Cr elevation &gt;= grade 2;Non-gradular cell decreased fever &gt;= grade 2;nausea/vomiting &gt;= grade 2; fatigue &gt;= grade 3; weight loss &gt;= grade 3;gastritis &gt;= grade 3; dairrea &gt;= grade 3; abdominal pain &gt;= grade 3; pancreatitis &gt;= grade 2; upper gastrointestinal bleeding &gt;= grade 2;other toxic reaction &gt;= grade 3;KPS &lt; 50 during the treatment</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Rectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>1000mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capecitabine 1000mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capecitabine 1200mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capecitabine 1400mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1500mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capecitabine 1500mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.</description>
    <arm_group_label>1000mg</arm_group_label>
    <other_name>stair 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.</description>
    <arm_group_label>1200mg</arm_group_label>
    <other_name>stair 2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>oral pills, 1400mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.</description>
    <arm_group_label>1400mg</arm_group_label>
    <other_name>stair 3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.</description>
    <arm_group_label>1500mg</arm_group_label>
    <other_name>stair 4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  rectal adenocarcinoma, pathological stage II/III(T3-4 or N+, UICC 2002), radical
             surgery received.

          -  interval between surgery and enrollment no less than two week and no more than 3
             months.

          -  KPS status no less than 70; life expectancy no less than 6 months.

          -  without life-threatening complications, such as severe hypertension, coronary heart
             disease, cerebral vascular disease, uncontrolled diabetes, etc.

          -  without severe drug allergy history.

          -  hemoglobin &gt;= 100g/L, white blood cell &gt;= 3.5*10E9/L, neutrophil &gt;= 1.5*10E9/L,
             platelet &gt;= 100*10E9/L.

          -  Creatin &lt;= 1.5* ULN(upper limit of normal), Total bilirubin &lt;= 2.5 ULN, AST and AST &lt;=
             2.5* ULN, AKP &lt;= 2.5*ULN

          -  do not receive chemotherapy before six months from enrollment.

          -  no previously pelvic irradiation history

          -  informed consent signed

        Exclusion Criteria:

          -  other cancer history, except curable non-melanoma skin cancer or cervix in-situ
             carcinoma

          -  allergy history to thymidine phosphorylase

          -  previous pelvic irradiation history

          -  receiving adjuvant chemotherapy in six months before enrollment

          -  active infection existed

          -  severe complication, such as acute myocardial infarction in 6 months, uncontrolled
             diabetes ( Plasma glucose concentrations in any time of a day≥11.1mmol/L）, severe
             cardiac arrhythmia， etc.

          -  life expectancy less than 6 months

          -  estimated cannot finish treatment

          -  attend other clinical trials in four weeks before enrollment

          -  receive other anti-cancer treatment currently

          -  other conditions which regarded illegal by censors with full reasons. for example,
             some conditions may conflict from the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>71 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Jin, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>radiation department, cancer hospital, CAMS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yexiong Li, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiation Department, Cancer Hospital, CAMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>radiation department, Cancer Hospital, CAMS</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet. 2001 Oct 20;358(9290):1291-304.</citation>
    <PMID>11684209</PMID>
  </reference>
  <reference>
    <citation>Tveit KM, Guldvog I, Hagen S, Trondsen E, Harbitz T, Nygaard K, Nilsen JB, Wist E, Hannisdal E. Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group. Br J Surg. 1997 Aug;84(8):1130-5.</citation>
    <PMID>9278661</PMID>
  </reference>
  <reference>
    <citation>Fisher B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerham DL, Fisher ER, Caplan R, Jones J, Lerner H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst. 1988 Mar 2;80(1):21-9.</citation>
    <PMID>3276900</PMID>
  </reference>
  <reference>
    <citation>Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, Kubista TP, Poon MA, Meyers WC, Mailliard JA, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991 Mar 14;324(11):709-15.</citation>
    <PMID>1997835</PMID>
  </reference>
  <reference>
    <citation>Wolmark N, Wieand HS, Hyams DM, Colangelo L, Dimitrov NV, Romond EH, Wexler M, Prager D, Cruz AB Jr, Gordon PH, Petrelli NJ, Deutsch M, Mamounas E, Wickerham DL, Fisher ER, Rockette H, Fisher B. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst. 2000 Mar 1;92(5):388-96.</citation>
    <PMID>10699069</PMID>
  </reference>
  <reference>
    <citation>Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med. 1985 Jun 6;312(23):1465-72.</citation>
    <PMID>2859523</PMID>
  </reference>
  <reference>
    <citation>Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001 Apr 15;19(8):2282-92.</citation>
    <PMID>11304782</PMID>
  </reference>
  <reference>
    <citation>Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P; Xeloda Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001 Nov 1;19(21):4097-106.</citation>
    <PMID>11689577</PMID>
  </reference>
  <reference>
    <citation>Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, Marshall JL, Mitchell EP, Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A, Schilsky RL. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer. 2004 Mar 22;90(6):1190-7.</citation>
    <PMID>15026800</PMID>
  </reference>
  <reference>
    <citation>Zhu AX, Willett CG. Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer. Semin Radiat Oncol. 2003 Oct;13(4):454-68. Review.</citation>
    <PMID>14586834</PMID>
  </reference>
  <reference>
    <citation>Souglakos J, Androulakis N, Mavroudis D, Kourousis C, Kakolyris S, Vardakis N, Kalbakis K, Pallis A, Ardavanis A, Varveris C, Georgoulias V. Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer. Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1284-7.</citation>
    <PMID>12873672</PMID>
  </reference>
  <reference>
    <citation>Dunst J, Reese T, Sutter T, Zühlke H, Hinke A, Kölling-Schlebusch K, Frings S. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol. 2002 Oct 1;20(19):3983-91.</citation>
    <PMID>12351595</PMID>
  </reference>
  <reference>
    <citation>Ngan SY, Michael M, Mackay J, McKendrick J, Leong T, Lim Joon D, Zalcberg JR. A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer. Br J Cancer. 2004 Sep 13;91(6):1019-24.</citation>
    <PMID>15305186</PMID>
  </reference>
  <reference>
    <citation>Aapro MS, Köhne CH, Cohen HJ, Extermann M. Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist. 2005 Mar;10(3):198-204. Review.</citation>
    <PMID>15793223</PMID>
  </reference>
  <reference>
    <citation>Folprecht G, Cunningham D, Ross P, Glimelius B, Di Costanzo F, Wils J, Scheithauer W, Rougier P, Aranda E, Hecker H, Köhne CH. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol. 2004 Sep;15(9):1330-8.</citation>
    <PMID>15319237</PMID>
  </reference>
  <reference>
    <citation>Jin J, Li YX, Liu YP, Wang WH, Song YW, Li T, Li N, Yu ZH, Liu XF. A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer. Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):725-9. Epub 2005 Oct 19.</citation>
    <PMID>16242260</PMID>
  </reference>
  <reference>
    <citation>Abir F, Alva S, Longo WE. The management of rectal cancer in the elderly. Surg Oncol. 2004 Dec;13(4):223-34. Review.</citation>
    <PMID>15615660</PMID>
  </reference>
  <reference>
    <citation>Pasetto LM, Monfardini S. The role of capecitabine in the treatment of colorectal cancer in the elderly. Anticancer Res. 2006 May-Jun;26(3B):2381-6. Review.</citation>
    <PMID>16821620</PMID>
  </reference>
  <reference>
    <citation>Dobie SA, Warren JL, Matthews B, Schwartz D, Baldwin LM, Billingsley K. Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population. Cancer. 2008 Feb 15;112(4):789-99. doi: 10.1002/cncr.23244.</citation>
    <PMID>18189291</PMID>
  </reference>
  <reference>
    <citation>Papamichael D, Audisio R, Horiot JC, Glimelius B, Sastre J, Mitry E, Van Cutsem E, Gosney M, Köhne CH, Aapro M; SIOG. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol. 2009 Jan;20(1):5-16. doi: 10.1093/annonc/mdn532. Epub 2008 Oct 15. Review.</citation>
    <PMID>18922882</PMID>
  </reference>
  <reference>
    <citation>Fiorica F, Cartei F, Carau B, Berretta S, Spartà D, Tirelli U, Santangelo A, Maugeri D, Luca S, Leotta C, Sorace R, Berretta M. Adjuvant radiotherapy on older and oldest elderly rectal cancer patients. Arch Gerontol Geriatr. 2009 Jul-Aug;49(1):54-9. doi: 10.1016/j.archger.2008.05.001. Epub 2008 Jun 24.</citation>
    <PMID>18573548</PMID>
  </reference>
  <reference>
    <citation>Surgery for colorectal cancer in elderly patients: a systematic review. Colorectal Cancer Collaborative Group. Lancet. 2000 Sep 16;356(9234):968-74. Review.</citation>
    <PMID>11041397</PMID>
  </reference>
  <reference>
    <citation>Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002 Mar 1;20(5):1192-202.</citation>
    <PMID>11870160</PMID>
  </reference>
  <reference>
    <citation>Bouvier AM, Launoy G, Lepage C, Faivre J. Trends in the management and survival of digestive tract cancers among patients aged over 80 years. Aliment Pharmacol Ther. 2005 Aug 1;22(3):233-41.</citation>
    <PMID>16091061</PMID>
  </reference>
  <reference>
    <citation>Goldberg RM, Tabah-Fisch I, Bleiberg H, de Gramont A, Tournigand C, Andre T, Rothenberg ML, Green E, Sargent DJ. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006 Sep 1;24(25):4085-91. Erratum in: J Clin Oncol. 2008 Jun 10;26(17):2925-6.</citation>
    <PMID>16943526</PMID>
  </reference>
  <reference>
    <citation>Feliu J, Sereno M, Castro JD, Belda C, Casado E, González-Barón M. Chemotherapy for colorectal cancer in the elderly: Whom to treat and what to use. Cancer Treat Rev. 2009 May;35(3):246-54. doi: 10.1016/j.ctrv.2008.11.004. Epub 2009 Apr 2. Review.</citation>
    <PMID>19345021</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2010</study_first_submitted>
  <study_first_submitted_qc>January 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2011</study_first_posted>
  <results_first_submitted>March 5, 2015</results_first_submitted>
  <results_first_submitted_qc>March 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 17, 2015</results_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jing Jin, M.D.</investigator_full_name>
    <investigator_title>vice chair of radiation department</investigator_title>
  </responsible_party>
  <keyword>rectal neoplasms</keyword>
  <keyword>aged</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>drug therapy</keyword>
  <keyword>dose-escalation</keyword>
  <keyword>capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between October 2010 and November 2013, 18 patients were enrolled in a hospital.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>1000mg</title>
          <description>capecitabine 1000mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
Capecitabine: oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.</description>
        </group>
        <group group_id="P2">
          <title>1200mg</title>
          <description>capecitabine 1200mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
Capecitabine: oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.</description>
        </group>
        <group group_id="P3">
          <title>1400mg</title>
          <description>capecitabine 1400mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
Capecitabine: oral pills, 1400mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.</description>
        </group>
        <group group_id="P4">
          <title>1500mg</title>
          <description>capecitabine 1500mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
Capecitabine: oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1000mg</title>
          <description>capecitabine 500mg/m2 twice daily. 6 patients enrolled</description>
        </group>
        <group group_id="B2">
          <title>1200mg</title>
          <description>capecitabine 600mg/m2 twice daily. 3 patients enrolled</description>
        </group>
        <group group_id="B3">
          <title>1400mg</title>
          <description>capecitabine 700mg/m2 twice daily. 3 patients enrolled</description>
        </group>
        <group group_id="B4">
          <title>1500mg</title>
          <description>capecitabine 750mg/m2 twice daily. 6 patients enrolled</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.5" lower_limit="72" upper_limit="83"/>
                    <measurement group_id="B2" value="73.7" lower_limit="73" upper_limit="75"/>
                    <measurement group_id="B3" value="75.7" lower_limit="71" upper_limit="81"/>
                    <measurement group_id="B4" value="73.5" lower_limit="70" upper_limit="78"/>
                    <measurement group_id="B5" value="74.5" lower_limit="70" upper_limit="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dose Related Toxicity</title>
        <description>dose related toxicity is defined as follows:1. WBC damage &gt;= grade 3; granular cell decrease &gt;= grade 3; hemoglobin &gt;= grade 2; platelet &gt;= grade 2;SGPT/SGOT elevation &gt;= grade 2; ALP &gt;= grade 2; GGT &gt;= grade 2; Tbil &gt;= grade 2;renal function damage: BUN/Cr elevation &gt;= grade 2;Non-gradular cell decreased fever &gt;= grade 2;nausea/vomiting &gt;= grade 2; fatigue &gt;= grade 3; weight loss &gt;= grade 3;gastritis &gt;= grade 3; dairrea &gt;= grade 3; abdominal pain &gt;= grade 3; pancreatitis &gt;= grade 2; upper gastrointestinal bleeding &gt;= grade 2;other toxic reaction &gt;= grade 3;KPS &lt; 50 during the treatment</description>
        <time_frame>up to 9 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1000mg</title>
            <description>capecitabine 1000mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
Capecitabine: oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.</description>
          </group>
          <group group_id="O2">
            <title>1200mg</title>
            <description>capecitabine 1200mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
Capecitabine: oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.</description>
          </group>
          <group group_id="O3">
            <title>1400mg</title>
            <description>capecitabine 1400mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
Capecitabine: oral pills, 1400mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.</description>
          </group>
          <group group_id="O4">
            <title>1500mg</title>
            <description>capecitabine 1500mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
Capecitabine: oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Dose Related Toxicity</title>
          <description>dose related toxicity is defined as follows:1. WBC damage &gt;= grade 3; granular cell decrease &gt;= grade 3; hemoglobin &gt;= grade 2; platelet &gt;= grade 2;SGPT/SGOT elevation &gt;= grade 2; ALP &gt;= grade 2; GGT &gt;= grade 2; Tbil &gt;= grade 2;renal function damage: BUN/Cr elevation &gt;= grade 2;Non-gradular cell decreased fever &gt;= grade 2;nausea/vomiting &gt;= grade 2; fatigue &gt;= grade 3; weight loss &gt;= grade 3;gastritis &gt;= grade 3; dairrea &gt;= grade 3; abdominal pain &gt;= grade 3; pancreatitis &gt;= grade 2; upper gastrointestinal bleeding &gt;= grade 2;other toxic reaction &gt;= grade 3;KPS &lt; 50 during the treatment</description>
          <units>event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1000mg</title>
          <description>capecitabine 1000mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
Capecitabine: oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.</description>
        </group>
        <group group_id="E2">
          <title>1200mg</title>
          <description>capecitabine 1200mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
Capecitabine: oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.</description>
        </group>
        <group group_id="E3">
          <title>1400mg</title>
          <description>capecitabine 1400mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
Capecitabine: oral pills, 1400mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.</description>
        </group>
        <group group_id="E4">
          <title>1500mg</title>
          <description>capecitabine 1500mg/m2/d d1-14, d22-35 combined with concurrent radiotherapy will be given to enrolled patients.
Capecitabine: oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>leukopenia, grade 3</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea, grade 3</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>vomiting, grade 3</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>leukopenia, grade 1-2</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>vomiting, grade 1-2</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>diarrhea, grade 1-2</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>incontinence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>abodminal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin reation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>hand-foot syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jing Jin</name_or_title>
      <organization>Chinese Academic Medical Sciences</organization>
      <phone>010-87788503</phone>
      <email>tangyu.pumc@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

